Compare YieldMax NVDA Option Income Strategy ETF (NVDY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax NVDA Option Income Strategy ETF vs Recursion Pharmaceuticals Inc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.67, while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B). Which is the better fit depends on your goals.
| NVDY | RXRX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $6.79 |
52-Week Low | $11.58 | $2.84 |
Market Cap | — | $1.74B |
Enterprise Value | — | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDY trades at $12.82, down 1.23% today, with technical indicators showing a bullish trend from moving averages while oscillators remain neutral. The ETF generates consistent weekly dividends but faces structural limitations in capturing Nvidia's full upside potential. Recent analyst downgrades highlight concerns about declining volatility reducing option income effectiveness and potential NAV erosion despite the attractive 39.7% annualized distribution rate.
The outlook remains cautious as NVDY's strategy sacrifices long-term capital appreciation for income generation. While weekly distributions provide cash flow, the fund's structural cap on upside participation and reliance on Nvidia's volatility create headwinds. Investors seeking pure Nvidia exposure may find better alternatives, while income-focused investors should weigh the high distribution rate against potential principal erosion.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
